Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487263 | 0.88 | GPR119 (0.46) | GPR119IDO1TDO2IDO2TBK1 | |
| SCHEMBL20571263 | 0.86 | NOTUM (0.43) | NOTUMFAAH | |
| SCHEMBL20571739 | 0.86 | ATM (0.39) | NOTUM | |
| SCHEMBL20567150 | 0.84 | MGLL (0.46) | FAAH | |
| SCHEMBL30302082 | 0.84 | MGLL (0.46) | FAAH | |
| SCHEMBL25639745 | 0.83 | IRAK4 (0.36) | GPR119IDO1TDO2IDO2NOTUM | |
| SCHEMBL20503582 | 0.81 | MGLL (0.46) | GPR119P2RY14 | |
| SCHEMBL20571730 | 0.79 | GPR119 (0.51) | GPR119 | |
| SCHEMBL23015481 | 0.79 | NOTUM (0.35) | NOTUM | |
| SCHEMBL20566886 | 0.78 | FAAH (0.50) | IDO1TDO2IDO2VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| CN-110678456-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| CN-110678456-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | GPR119 308/4885IDO1 3336/4885TDO2 4114/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | GPR119 308/4885IDO1 3336/4885TDO2 4114/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | GPR119 353/4885IDO1 3331/4885TDO2 4046/4885 |
| US-10266497-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | GPR119 308/4885IDO1 3336/4885TDO2 4114/4885 |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | GPR119 308/4885IDO1 3336/4885TDO2 4114/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | GPR119 353/4885IDO1 3331/4885TDO2 4046/4885 |
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | GPR119 308/4885IDO1 3336/4885TDO2 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.